Role of PARP inhibitors in prostate cancer
DSB may develop as a result of DNA replication if SSB goes unrepaired [17]. Because replication forks can break when they come into contact with a SSB, homologous recombination is an essential mechanism for repairing replication forks and preventing fork collapse [18]. CURRENT APPLICATIONS AND STUDY...
Gespeichert in:
| Veröffentlicht in: | Central European journal of urology 2024-07, Vol.77 (3), p.424-435 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 435 |
|---|---|
| container_issue | 3 |
| container_start_page | 424 |
| container_title | Central European journal of urology |
| container_volume | 77 |
| creator | Szczotka, Julia Szpila, Gabriela Hejduk, Michał Mucha, Ewa Rudel, Jolanta Kępiński, Michał Kaletka, Julia Ryszawy, Jakub Zapala, Piotr Tsuboi, Ichiro Matsukawa, Akihiro Miszczyk, Marcin Fazekas, Tamas Zattoni, Fabio Bryniarski, Piotr Rajwa, Paweł |
| description | DSB may develop as a result of DNA replication if SSB goes unrepaired [17]. Because replication forks can break when they come into contact with a SSB, homologous recombination is an essential mechanism for repairing replication forks and preventing fork collapse [18]. CURRENT APPLICATIONS AND STUDY RESULTS OF PARP INHIBITORS Olaparib In December 2014, olaparib (Lynparza, Astra Zeneca AB, and Merck) was approved in the European Union and the United States for the treatment of advanced ovarian cancer and breast cancer with BRCA1/2 gene mutations [25]. Patients with deleterious or suspected deleterious gBRCAm, HER2-negative (no human epidermal growth factor receptor type 2) metastatic breast cancer who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting are eligible for treatment with Lynparza [26]. [...]the median overall survival (0S) was 18.5 months for patients in the olaparib arm compared to 15.1 months for those in the control group [28]. |
| doi_str_mv | 10.5173/ceju.2024.72.R1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_3144139295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3144139295</sourcerecordid><originalsourceid>FETCH-proquest_journals_31441392953</originalsourceid><addsrcrecordid>eNqNijsLwjAYRT9EwaKdXQNuQmOefYwiimMp7qWWFBNKo0n6_80gzt7lHjgHYEcJlrTgx16ZGTPCBC4YbugCEkZKkomy4Msfk3wNqfeGxOWlyKVM4NDYUSE7oPrU1EhPT_3QwTofEb2c9aELCvXd1Cu3hdXQjV6l39_A_nq5n29Z7N6z8qE1dnZTVC2nQlBesUry_6oPIao3tg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3144139295</pqid></control><display><type>article</type><title>Role of PARP inhibitors in prostate cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Szczotka, Julia ; Szpila, Gabriela ; Hejduk, Michał ; Mucha, Ewa ; Rudel, Jolanta ; Kępiński, Michał ; Kaletka, Julia ; Ryszawy, Jakub ; Zapala, Piotr ; Tsuboi, Ichiro ; Matsukawa, Akihiro ; Miszczyk, Marcin ; Fazekas, Tamas ; Zattoni, Fabio ; Bryniarski, Piotr ; Rajwa, Paweł</creator><creatorcontrib>Szczotka, Julia ; Szpila, Gabriela ; Hejduk, Michał ; Mucha, Ewa ; Rudel, Jolanta ; Kępiński, Michał ; Kaletka, Julia ; Ryszawy, Jakub ; Zapala, Piotr ; Tsuboi, Ichiro ; Matsukawa, Akihiro ; Miszczyk, Marcin ; Fazekas, Tamas ; Zattoni, Fabio ; Bryniarski, Piotr ; Rajwa, Paweł</creatorcontrib><description>DSB may develop as a result of DNA replication if SSB goes unrepaired [17]. Because replication forks can break when they come into contact with a SSB, homologous recombination is an essential mechanism for repairing replication forks and preventing fork collapse [18]. CURRENT APPLICATIONS AND STUDY RESULTS OF PARP INHIBITORS Olaparib In December 2014, olaparib (Lynparza, Astra Zeneca AB, and Merck) was approved in the European Union and the United States for the treatment of advanced ovarian cancer and breast cancer with BRCA1/2 gene mutations [25]. Patients with deleterious or suspected deleterious gBRCAm, HER2-negative (no human epidermal growth factor receptor type 2) metastatic breast cancer who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting are eligible for treatment with Lynparza [26]. [...]the median overall survival (0S) was 18.5 months for patients in the olaparib arm compared to 15.1 months for those in the control group [28].</description><identifier>ISSN: 2080-4806</identifier><identifier>EISSN: 2080-4873</identifier><identifier>DOI: 10.5173/ceju.2024.72.R1</identifier><language>eng</language><publisher>Warsaw: Polish Urological Association</publisher><subject>Breast cancer ; Cancer therapies ; Cell cycle ; Cell death ; Chemotherapy ; Enzymes ; FDA approval ; Genes ; Literature reviews ; Metastasis ; Mutation ; Ovarian cancer ; Prostate cancer ; Side effects</subject><ispartof>Central European journal of urology, 2024-07, Vol.77 (3), p.424-435</ispartof><rights>Copyright Polish Urological Association 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Szczotka, Julia</creatorcontrib><creatorcontrib>Szpila, Gabriela</creatorcontrib><creatorcontrib>Hejduk, Michał</creatorcontrib><creatorcontrib>Mucha, Ewa</creatorcontrib><creatorcontrib>Rudel, Jolanta</creatorcontrib><creatorcontrib>Kępiński, Michał</creatorcontrib><creatorcontrib>Kaletka, Julia</creatorcontrib><creatorcontrib>Ryszawy, Jakub</creatorcontrib><creatorcontrib>Zapala, Piotr</creatorcontrib><creatorcontrib>Tsuboi, Ichiro</creatorcontrib><creatorcontrib>Matsukawa, Akihiro</creatorcontrib><creatorcontrib>Miszczyk, Marcin</creatorcontrib><creatorcontrib>Fazekas, Tamas</creatorcontrib><creatorcontrib>Zattoni, Fabio</creatorcontrib><creatorcontrib>Bryniarski, Piotr</creatorcontrib><creatorcontrib>Rajwa, Paweł</creatorcontrib><title>Role of PARP inhibitors in prostate cancer</title><title>Central European journal of urology</title><description>DSB may develop as a result of DNA replication if SSB goes unrepaired [17]. Because replication forks can break when they come into contact with a SSB, homologous recombination is an essential mechanism for repairing replication forks and preventing fork collapse [18]. CURRENT APPLICATIONS AND STUDY RESULTS OF PARP INHIBITORS Olaparib In December 2014, olaparib (Lynparza, Astra Zeneca AB, and Merck) was approved in the European Union and the United States for the treatment of advanced ovarian cancer and breast cancer with BRCA1/2 gene mutations [25]. Patients with deleterious or suspected deleterious gBRCAm, HER2-negative (no human epidermal growth factor receptor type 2) metastatic breast cancer who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting are eligible for treatment with Lynparza [26]. [...]the median overall survival (0S) was 18.5 months for patients in the olaparib arm compared to 15.1 months for those in the control group [28].</description><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell death</subject><subject>Chemotherapy</subject><subject>Enzymes</subject><subject>FDA approval</subject><subject>Genes</subject><subject>Literature reviews</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Prostate cancer</subject><subject>Side effects</subject><issn>2080-4806</issn><issn>2080-4873</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNijsLwjAYRT9EwaKdXQNuQmOefYwiimMp7qWWFBNKo0n6_80gzt7lHjgHYEcJlrTgx16ZGTPCBC4YbugCEkZKkomy4Msfk3wNqfeGxOWlyKVM4NDYUSE7oPrU1EhPT_3QwTofEb2c9aELCvXd1Cu3hdXQjV6l39_A_nq5n29Z7N6z8qE1dnZTVC2nQlBesUry_6oPIao3tg</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Szczotka, Julia</creator><creator>Szpila, Gabriela</creator><creator>Hejduk, Michał</creator><creator>Mucha, Ewa</creator><creator>Rudel, Jolanta</creator><creator>Kępiński, Michał</creator><creator>Kaletka, Julia</creator><creator>Ryszawy, Jakub</creator><creator>Zapala, Piotr</creator><creator>Tsuboi, Ichiro</creator><creator>Matsukawa, Akihiro</creator><creator>Miszczyk, Marcin</creator><creator>Fazekas, Tamas</creator><creator>Zattoni, Fabio</creator><creator>Bryniarski, Piotr</creator><creator>Rajwa, Paweł</creator><general>Polish Urological Association</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20240701</creationdate><title>Role of PARP inhibitors in prostate cancer</title><author>Szczotka, Julia ; Szpila, Gabriela ; Hejduk, Michał ; Mucha, Ewa ; Rudel, Jolanta ; Kępiński, Michał ; Kaletka, Julia ; Ryszawy, Jakub ; Zapala, Piotr ; Tsuboi, Ichiro ; Matsukawa, Akihiro ; Miszczyk, Marcin ; Fazekas, Tamas ; Zattoni, Fabio ; Bryniarski, Piotr ; Rajwa, Paweł</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_31441392953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell death</topic><topic>Chemotherapy</topic><topic>Enzymes</topic><topic>FDA approval</topic><topic>Genes</topic><topic>Literature reviews</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Prostate cancer</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szczotka, Julia</creatorcontrib><creatorcontrib>Szpila, Gabriela</creatorcontrib><creatorcontrib>Hejduk, Michał</creatorcontrib><creatorcontrib>Mucha, Ewa</creatorcontrib><creatorcontrib>Rudel, Jolanta</creatorcontrib><creatorcontrib>Kępiński, Michał</creatorcontrib><creatorcontrib>Kaletka, Julia</creatorcontrib><creatorcontrib>Ryszawy, Jakub</creatorcontrib><creatorcontrib>Zapala, Piotr</creatorcontrib><creatorcontrib>Tsuboi, Ichiro</creatorcontrib><creatorcontrib>Matsukawa, Akihiro</creatorcontrib><creatorcontrib>Miszczyk, Marcin</creatorcontrib><creatorcontrib>Fazekas, Tamas</creatorcontrib><creatorcontrib>Zattoni, Fabio</creatorcontrib><creatorcontrib>Bryniarski, Piotr</creatorcontrib><creatorcontrib>Rajwa, Paweł</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Central European journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szczotka, Julia</au><au>Szpila, Gabriela</au><au>Hejduk, Michał</au><au>Mucha, Ewa</au><au>Rudel, Jolanta</au><au>Kępiński, Michał</au><au>Kaletka, Julia</au><au>Ryszawy, Jakub</au><au>Zapala, Piotr</au><au>Tsuboi, Ichiro</au><au>Matsukawa, Akihiro</au><au>Miszczyk, Marcin</au><au>Fazekas, Tamas</au><au>Zattoni, Fabio</au><au>Bryniarski, Piotr</au><au>Rajwa, Paweł</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of PARP inhibitors in prostate cancer</atitle><jtitle>Central European journal of urology</jtitle><date>2024-07-01</date><risdate>2024</risdate><volume>77</volume><issue>3</issue><spage>424</spage><epage>435</epage><pages>424-435</pages><issn>2080-4806</issn><eissn>2080-4873</eissn><abstract>DSB may develop as a result of DNA replication if SSB goes unrepaired [17]. Because replication forks can break when they come into contact with a SSB, homologous recombination is an essential mechanism for repairing replication forks and preventing fork collapse [18]. CURRENT APPLICATIONS AND STUDY RESULTS OF PARP INHIBITORS Olaparib In December 2014, olaparib (Lynparza, Astra Zeneca AB, and Merck) was approved in the European Union and the United States for the treatment of advanced ovarian cancer and breast cancer with BRCA1/2 gene mutations [25]. Patients with deleterious or suspected deleterious gBRCAm, HER2-negative (no human epidermal growth factor receptor type 2) metastatic breast cancer who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting are eligible for treatment with Lynparza [26]. [...]the median overall survival (0S) was 18.5 months for patients in the olaparib arm compared to 15.1 months for those in the control group [28].</abstract><cop>Warsaw</cop><pub>Polish Urological Association</pub><doi>10.5173/ceju.2024.72.R1</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2080-4806 |
| ispartof | Central European journal of urology, 2024-07, Vol.77 (3), p.424-435 |
| issn | 2080-4806 2080-4873 |
| language | eng |
| recordid | cdi_proquest_journals_3144139295 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Breast cancer Cancer therapies Cell cycle Cell death Chemotherapy Enzymes FDA approval Genes Literature reviews Metastasis Mutation Ovarian cancer Prostate cancer Side effects |
| title | Role of PARP inhibitors in prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T23%3A15%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20PARP%20inhibitors%20in%20prostate%20cancer&rft.jtitle=Central%20European%20journal%20of%20urology&rft.au=Szczotka,%20Julia&rft.date=2024-07-01&rft.volume=77&rft.issue=3&rft.spage=424&rft.epage=435&rft.pages=424-435&rft.issn=2080-4806&rft.eissn=2080-4873&rft_id=info:doi/10.5173/ceju.2024.72.R1&rft_dat=%3Cproquest%3E3144139295%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3144139295&rft_id=info:pmid/&rfr_iscdi=true |